Searched over 200M research papers for "diuretic lisinopril"
10 papers analyzed
These studies suggest that lisinopril is effective in treating hypertension and heart failure, often showing superior efficacy and safety compared to other treatments like hydrochlorothiazide, captopril, and digoxin.
20 papers analyzed
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, and hydrochlorothiazide, a thiazide diuretic, are commonly used medications for managing hypertension and heart failure. Both drugs have distinct mechanisms of action and are often compared to determine their efficacy and safety in various patient populations.
In a multicenter, double-blind trial involving 232 obese hypertensive patients, both lisinopril and hydrochlorothiazide significantly reduced office diastolic and systolic blood pressures compared to placebo. Lisinopril showed a slightly higher efficacy in reducing diastolic pressure, with 60% of patients achieving a diastolic pressure below 90 mm Hg, compared to 43% with hydrochlorothiazide. Ambulatory blood pressure monitoring confirmed these findings, indicating that both medications effectively lower 24-hour blood pressure.
Lisinopril and hydrochlorothiazide have different impacts on metabolic parameters. Hydrochlorothiazide was associated with an increase in plasma glucose levels and a decrease in serum potassium, whereas lisinopril did not significantly affect insulin or lipid profiles and had a more favorable impact on plasma glucose.
A study comparing the effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology found that both drugs lowered blood pressure effectively without significantly altering platelet counts or aggregation. However, lisinopril showed a tendency to improve blood rheology by increasing erythrocyte aggregation time and decreasing disaggregation shear stress, suggesting potential benefits in reducing atherosclerotic and thrombotic complications.
A clinical trial assessed the feasibility of discontinuing diuretic therapy in stable congestive heart failure (CHF) patients while continuing background CHF therapy with either lisinopril or placebo. The study found that 29% of patients did not require reinitiation of diuretic therapy, and the probability of remaining diuretic-free was higher in patients with a lower baseline furosemide dose, higher left ventricular ejection fraction, and no history of systemic hypertension. This suggests that lisinopril may help maintain stability in certain CHF patients without the need for continuous diuretic therapy.
The FIXLINDA study evaluated the efficacy of a fixed-dose combination of lisinopril and the long-acting diuretic indapamide in hypertensive patients. The combination therapy was effective in achieving target blood pressure in a significant proportion of patients and improved circadian blood pressure and diuresis profiles. The treatment was well-tolerated with minimal adverse events.
A long-term study involving 466 hypertensive patients compared lisinopril monotherapy with a combination of lisinopril and the thiazide diuretic trichlormethiazide. Both treatment regimens effectively lowered blood pressure, but the combination therapy allowed for a lower maintenance dose of lisinopril and mitigated the increase in serum potassium observed with lisinopril monotherapy.
Lisinopril is an effective antihypertensive agent with favorable metabolic and rheological profiles compared to hydrochlorothiazide. It can be used as monotherapy or in combination with diuretics to enhance blood pressure control and improve patient outcomes. The choice between lisinopril and diuretics should consider individual patient characteristics, including metabolic risk factors and the need for long-term management of hypertension and heart failure.
Most relevant research papers on this topic